The biology of malignant breast tumors has an impact on the presentation in ultrasound: An analysis of 315 cases

BMC Women's Health

Volumn 13, Issue 1, 2013, Pages

  Wojcinski, S ^a   Stefanidou, N ^b   Hillemanns, P ^a   Degenhardt, F ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Helios Hospital Krefeld   (Germany)

^c FRANZISKUS HOSPITAL   (Germany)

Author keywords

Breast ultrasound; Cancer detection; Tumor biology; Ultrasound features

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR;

ADULT; AGE; ARTICLE; BREAST CARCINOMA; BREAST DENSITY; BREAST TUMOR; CONTRAST ENHANCEMENT; DENSITY; ECHOMAMMOGRAPHY; FALSE NEGATIVE RESULT; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; ULTRASOUND SCANNER; ULTRASOUND TRANSDUCER;

AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TRIPLE NEGATIVE BREAST NEOPLASMS; ULTRASONOGRAPHY, MAMMARY;

EID: 84888256468     PISSN: None     EISSN: 14726874     Source Type: Journal    
DOI: 10.1186/1472-6874-13-47     Document Type: Article

References (33)

1. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957, 11(3):359-377. 10.1038/bjc.1957.43, 2073885, 13499785.
2. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19(5):403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
3. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Richardson AL, Schnitt SJ, Schmitt FC, Tan PH, Tse GM, Badve S, Ellis IO. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 2010, 12(4):207. 2949637, 20804570.
4. Jensen EV, Jacobson HI. Fate of steroid estrogens in target tissues. Biological Activities of Steroids in Relation to Cancer 1960, 161-174. New York: NY: Academic, Pincus G, Vollmer E.
5. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984, 312(5994):513-516. 10.1038/312513a0, 6095109.
6. Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A. HER2 as a prognostic factor in breast cancer. Oncology 2001, 61(Suppl 2):67-72.
7. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007, 357(1):39-51. 10.1056/NEJMra043186, 17611206.
8. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007, 8(5):R76. 10.1186/gb-2007-8-5-r76, 1929138, 17493263.
9. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752. 10.1038/35021093, 10963602.
10. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98(19):10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
11. Stavros AT. Breast ultrasound: 1st ed 2004, Philadelphia, PA: Lippincott Williams & Wilkins.
12. Sadigh G, Carlos RC, Neal CH, Dwamena BA. Ultrasonographic differentiation of malignant from benign breast lesions: a meta-analytic comparison of elasticity and BIRADS scoring. Breast cancer research and treatment 2012, 133(1):23-35. 10.1007/s10549-011-1857-8, 22057974.
13. Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, Bohm-Velez M, Mahoney MC, Evans WP, 3rd Larsen LH, Morton MJ, Mendelson EB, Farria DM, Cormack JB, Marques HS, Adams A, Yeh NM, Gabrielli G. ACRIN 6666 Investigators: Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 2012, 307(13):1394-1404. 10.1001/jama.2012.388, 22474203.
14. Mendelson EB, Baum JK, Berg WA, Merritt CR, Rubin E. BI-RADS: Ultrasound. Breast Imaging Reporting and Data System: ACR BI-RADS - Breast Imaging Atlas 2002, Reston, VA: American College of Radiology, D'Orsi CJ, Mendelson EB, Ikeda DM.
15. Wojcinski S, Soliman AA, Schmidt J, Makowski L, Degenhardt F, Hillemanns P. Sonographic features of triple-negative and non-triple-negative breast cancer. J Ultrasound Med 2012, 31(10):1531-1541.
16. DEGUM (Deutsche Gesellschaft für Ultraschall in der Medizin, German Association for Ultrasound in Medicine) - Mehrstufenkonzept Mammasonographie [http://www.degum.de/Mehrstufenkonzept_Mammasonogra.634.0.html].
17. Madjar H, Ohlinger R, Mundinger A, Watermann D, Frenz JP, Bader W, Schulz-Wendtland R, Degenhardt F. BI-RADS-analogue DEGUM criteria for findings in breast ultrasound-consensus of the DEGUM Committee on Breast Ultrasound. Ultraschall Med 2006, 27(4):374-379. 10.1055/s-2006-926943, 16927216.
18. Cocquyt V, Van Belle S. Lobular carcinoma in situ and invasive lobular cancer of the breast. Curr Opin Obstet Gynecol 2005, 17(1):55-60.
19. Mann RM. The effectiveness of MR imaging in the assessment of invasive lobular carcinoma of the breast. Magn Reson Imaging Clin N Am 2010, 18(2):259-276. ix, 10.1016/j.mric.2010.02.005, 20494311.
20. Tan SM, Behranwala KA, Trott PA, Nasiri NA, Moskovic E, Brown G, King DM, Sacks NP, Gui GP. A retrospective study comparing the individual modalities of triple assessment in the pre-operative diagnosis of invasive lobular breast carcinoma. Eur J Surg Oncol 2002, 28(3):203-208. 10.1053/ejso.2001.1236, 11944950.
21. Watermann DO, Tempfer C, Hefler LA, Parat C, Stickeler E. Ultrasound morphology of invasive lobular breast cancer is different compared with other types of breast cancer. Ultrasound Med Biol 2005, 31(2):167-174. 10.1016/j.ultrasmedbio.2004.11.005, 15708454.
22. Kim SH, Cha ES, Park CS, Kang BJ, Whang IY, Lee AW, Song BJ, Park J. Imaging features of invasive lobular carcinoma: comparison with invasive ductal carcinoma. Jpn J Radiol 2011, 29(7):475-482. 10.1007/s11604-011-0584-8, 21882089.
23. Cheung YC, Chen SC, Lee KF, Wan YL, Ng SH. Sonographic and pathologic findings in typical and atypical medullary carcinomas of the breast. J Clin Ultrasound 2000, 28(7):325-331. 10.1002/1097-0096(200009)28:7<325::AID-JCU2>3.0.CO;2-4, 10934331.
24. Mitnick JS, Gianutsos R, Pollack AH, Susman M, Baskin BL, Ko WD, Pressman PI, Feiner HD, Roses DF. Tubular carcinoma of the breast: sensitivity of diagnostic techniques and correlation with histopathology. AJR Am J Roentgenol 1999, 172(2):319-323. 10.2214/ajr.172.2.9930775, 9930775.
25. Memis A, Ozdemir N, Parildar M, Ustun EE, Erhan Y. Mucinous (colloid) breast cancer: mammographic and US features with histologic correlation. Eur J Radiol 2000, 35(1):39-43. 10.1016/S0720-048X(99)00124-2, 10930764.
26. Yang WT, Muttarak M, Ho LW. Nonmammary malignancies of the breast: ultrasound, CT, and MRI. Semin Ultrasound CT MR 2000, 21(5):375-394. 10.1016/S0887-2171(00)90031-3, 11071618.
27. Wojcinski S, Farrokh A, Weh HJ, Williams J, Wiskirchen J. Degenhardt F: [Clinical Image: Breast metastasis from rectal carcinoma]. Senologie - Zeitschrift für Mammadiagnostik und -therapie 2012, 9:63-65.
28. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14(4):320-368. 10.1634/theoncologist.2008-0230, 19346299.
29. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26(45):6469-6487. 10.1038/sj.onc.1210477, 3021475, 17471238.
30. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjanen K. Hormone receptors as prognostic factors in female breast cancer. Ann Med 1991, 23(6):643-648. 10.3109/07853899109148097, 1777219.
31. Aho M, Irshad A, Ackerman SJ, Lewis M, Leddy R, Pope TL, Campbell AS, Cluver A, Wolf BJ, Cunningham JE. Correlation of sonographic features of invasive ductal mammary carcinoma with age, tumor grade, and hormone-receptor status. J Clin Ultrasound 2013, 41(1):10-17. 10.1002/jcu.21990, 22996916.
32. Soon PS, Vallentine J, Palmer A, Magarey CJ, Schwartz P, Morris DL. Echogenicity of breast cancer: is it of prognostic value?. Breast 2004, 13(3):194-199. 10.1016/j.breast.2004.01.008, 15177421.
33. Bullier B, Macgrogan G, Bonnefoi H, Hurtevent-Labrot G, Lhomme E, Brouste V, Boisserie-Lacroix M. Imaging features of sporadic breast cancer in women under 40 years old: 97 cases. Eur Radiol 2013, 23(12):3237-3245. 10.1007/s00330-013-2966-z, 23918218.